Are there benefits in routine clinical practice of continuing trastuzumab after progression for metastatic breast cancer patients?

Anti-Cancer Drugs

Volumn 23, Issue 10, 2012, Pages 1089-1098

  Esposito, Angela ^a   Munzone, Elisabetta ^a   Bagnardi, Vincenzo ^a,b,c   Adamoli, Laura ^a   Sciandivasci, Angela ^a   Cullurà, Daniela ^a   Goldhirsch, Aron ^a   Nolè, Franco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c Frontier Science and Technology Research Foundation Southern Europe   (Switzerland)

Author keywords

cancer therapy; metastatic breast cancer; prolonged administration; target therapy; trastuzumab beyond progression

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; AGED; AMENORRHEA; ARTICLE; BONE METASTASIS; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CANCER THERAPY; CARDIOTOXICITY; CLINICAL PRACTICE; DRUG EFFICACY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FLUORESCENCE IN SITU HYBRIDIZATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOHISTOCHEMISTRY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; SOFT TISSUE METASTASIS; TREATMENT DURATION; VISCERA METASTASIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENES, ERBB-2; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84867575061     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835679d3     Document Type: Article

References (61)

1. Slamon DJ. Proto-oncogenes and human cancers. N Engl J Med 1987; 317:955-957.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182.
3. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-712.
4. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993; 11:1936-1942.
5. Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers - a review. Gene 1995; 159:19-27.
6. Arteaga CL, Chinratanalab W, Carter MB. Inhibitors of HER2/neu (erbB-2) signal transduction. Semin Oncol 2001; 28 (Suppl 18):30-35.
7. Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 2001; 12 (Suppl 1):S35-S41.
8. Baselga J, Albanell J, Molina MA, Arribas J. Mechanism of action of trastuzumab and scientific update. Semin Oncol 2001; 28 (Suppl 16): 4-11.
9. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006; 3:269-280.
10. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-726.
11. Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23:2162-2171.
12. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
13. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2- overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 1800-1808.
14. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, et al. Trastuzumab and vinorelbine as first-line therapy for HER2- overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003; 21:2889-2895.
15. Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004; 96:759-769.
16. Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Rudas M, Mader RM, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007; 25:3853-3858.
17. O'Shaughnessy JA, Vukelja S, Marsland T. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 2004; 5:142-147.
18. Mackey JR, Kaufman B, Clemens M, Bapsy PP, Vaid A, Wardley A, et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer [abstract #3]. Breast Cancer Res Treat 2006; 100 (Suppl 1):6.
19. Marcom PK, Isaacs C, Harris L,Wong ZW, Kommarreddy A, Novielli N, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007; 102:43-49.
20. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28:1124-1130.
21. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). Onkologie 2005; 28:582-586.
22. Extra JM, Antoine EC, Vincent-Salomon A, Delozier T, Kerbrat P, Bethune- Volters A, et al. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: The observational Hermine study. Oncologist 2010; 15:799-809.
23. Bartsch R,Wenzel C, Hussian D, Pluschnig U, Sevelda U, Koestler W, et al. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study. BMC Cancer 2006; 6:63.
24. Gelmon KA, Mackey J, Verma S, Gertler SZ, Bangemann N, Klimo P, et al. Use of trastuzumab beyond disease progression: Observations from a retrospective review of case histories. Clin Breast Cancer 2004; 5:52-58, discussion 59-62.
25. Von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German breast group 26/ breast international group 03-05 study. J Clin Oncol 2009; 27:1999-2006.
26. Yeon CH, Slamon D, Patel R, Cartmell A, Leyland-Jones B, Klein P, et al. Clinical benefit of trastuzumab (H) among patients with HER2-positive metastatic breast cancer (MBC) not achieving objective responses when treated with H plus chemotherapy (CT) [abstract]. Proc Am Soc Clin Oncol 2004; 22:680.
27. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ, et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96: 739-749.
28. Chien KR. Stress pathways and heart failure. Cell 1999; 98:555-558.
29. Chien KR. Herceptin and the heart - a molecular modifier of cardiac failure. N Engl J Med 2006; 354:789-790.
30. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23:7820-7826.
31. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. J Clin Oncol 2007; 25:3525-3533.
32. Valero V, Gill E, Paton VE, Chang HY, Buzdar AU, Park G, et al. Normal cardiac biopsy results following co-administration of doxorubicin (A), cyclophosphamide (C) and trastuzumab (H) to women with HER2-positive metastatic breast cancer [abstract 572]. J Clin Oncol 2004; 23 (Suppl):20s.
33. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20:1215-1221.
34. Cancello G, Montagna E, D'Agostino D, Giuliano M, Giordano A, Di Lorenzo G, et al. Continuing trastuzumab beyond disease progression: Outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res 2008; 10:R60.
35. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18:2241-2251.
36. Pegram MD, Lopez A, Konecny G, Slamon DJ. Trastuzumab and chemotherapeutics: Drug interactions and synergies. Semin Oncol 2000; 27 (Suppl 11):21-25.
37. Bachelot T, Mauriac L, Delcambre C. Efficacy and safety of trastuzumab plus vinorelbine as second-line treatment for women with HER2-positive metastatic breast cancer beyond disease progression [abstract 1094]. J Clin Oncol 2007; 25 (Suppl):55s.
38. Von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, et al. Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer 2011; 47:2273-2281.
39. PANDORA study. A study of herceptin in combination with 2nd-line chemotherapy in patients with HER2 positive metastatic breast cancer. Available at: http://www.cancer.gov [Accessed 02 April 2012].
40. THOR study. A study of continued herceptin in combination with second line chemotherapy in patients with HER2 positive metastatic Breast Cancer. Available at: http://www.cancer.gov [Accessed 02 April 2012].
41. Metro G, Giannarelli D, Gemma D, Lanzetta G, Ciccarese M, Papaldo P, et al. Time to first tumor progression as outcome predictor of a second trasuzumab based therapy beyond progression in HER-2 positive metastatic. Breast J 2010; 16:66-72.
42. Hayashi M, Okumura Y, Osako T, Toyozumi Y, Arima N, Iwase H, et al. Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer. Int J Clin Oncol 2011; 16:694-700.
43. Leyland-Jones B. Dose scheduling: Herceptin. Oncology 2001; 61 (Suppl 2):31-36.
44. Leyland-Jones B, Colomer R, Trudeau M,Wardley A. Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. J Clin Oncol 2010; 28:960-966.
45. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-2648.
46. Speyer J. Cardiac dysfunction in the trastuzumab clinical experience [editorial]. J Clin Oncol 2002; 20:1156-1157.
47. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004; 22:1063-1070.
48. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733-2743.
49. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2:127-137.
50. Baselga J, Gelmon KA, Verma S,Wardley A, Conte P, Miles D, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28:1138-1144.
51. Portera CC, Walshe JM, Rosing DR, Denduluri N, Berman AW, Vatas U, et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 2008; 14:2710-2716.
52. A study of a combination of trastuzumab and capecitabine with or without pertuzumab in patients with HER2-positive metastatic breast cancer (PHEREXA). Available at: http://www.cancer.gov [Accessed 02 April 2012].
53. A study to evaluate pertuzumab + trastuzumab +docetaxel vs. placebo+trastuzumab +docetaxel in previously untreated Her2-positive metastatic breast cancer (CLEOPATRA). Available at: http:// www.cancer.gov [Accessed 02 April 2012].
54. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibodycytotoxic drug conjugate. Cancer Res 2008; 68:9280-9290.
55. Perez EA, Dirix L, Kocsis J, Gianni L, Lu J, Vinholes J, et al. Efficacy and safety of trastuzumab-DM1 vs trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: Preliminary results of a randomized, multicenter, open-label phase 2 study (TDM4450G) [abstract LBA3]. Ann Oncol 2010; 21:viii2.
56. Hurvitz S, Dirix L, Kocsis J, Gianni L, Lu J, Vinholes J, et al. Trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H-T) in previouslyuntreated HER2-positive metastatic breast cancer (MBC): Primary results of a randomized, multicenter, open-label phase II study (TDM4450g/ B021976). Eur J Cancer 2011; 47:S330Abstract 5001.
57. Dieras V, Harbeck N, Albain K, Burris H, Awada A, Crivellari D, et al. A phase Ib/II trial of trastuzumab- DM1 with pertuzumab for patients with HER2- positive, locally advanced or metastatic breast cancer: Interim efficacy and safety results [abstract P3-14-01]. Presented at 33rd Annual San Antonio Breast Cancer Symposium; 8-12 December 2010; San Antonio, TX.
58. A study of trastuzumab emtansine (T-DM1) plus pertuzumab/pertuzumab placebo versus trastuzumab [Herceptin] plus a taxane in patients with metastatic breast cancer (MARIANNE). Available at: http://www.cancer.gov [Accessed 02 April 2012].
59. A study of trastuzumab emtansine (T-DM1) in combination with docetaxel, and potentially pertuzumab, in patients with advanced breast cancer. Available at: http://www.cancer.gov [Accessed 02 April 2012].
60. An open-label study of trastuzumab emtansine (T-DM1) vs capecitabine + lapatinib in patients with HER2-positive locally advanced or metastatic breast cancer (EMILIA). Available at: http://www.cancer.gov [Accessed 02 April 2012].
61. A study of the efficacy and safety of trastuzumab-MCC-DM1 vs. trastuzumab (Herceptins) and docetaxel (Taxoteres) in patients with metastatic HER2-positive breast cancer who have not received prior chemotherapy for metastatic disease. Available at: http://www.cancer.gov [Accessed 02 April 2012].